Patent intelligence · US
US 11622968
Heterocyclic modulators of lipid synthesis
Heterocyclic modulators of lipid synthesis
Patent details — US 11622968
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 11, 2023
- Expiration
- Apr 6, 2043
- Applicant
- Sagimet Biosciences Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/451, A61K31/4525
Quick answer
US 11622968 (Heterocyclic modulators of lipid synthesis) is held by Sagimet Biosciences Inc.. Status: granted. Granted Apr 11, 2023. Expires Apr 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sagimet Biosciences Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/451, A61K31/4525, A61K31/453, A61K31/454
Related coverage
Frequently asked questions
What is US patent 11622968?
US 11622968 (Heterocyclic modulators of lipid synthesis) is held by Sagimet Biosciences Inc.. Status: granted. Granted Apr 11, 2023. Expires Apr 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11622968?
Sagimet Biosciences Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11622968 expire?
Our index shows an expiration date of Apr 6, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.